PMI is currently assessing the risk reduction potential of a portfolio of candidate reduced risk products that we are developing. This PMI-hosted poster session will be an opportunity to hear about the systems toxicology-based approaches PMI is using to assess these new products and to allow you to share your views on our research.
Application of Systems Pharmacology to Identify Exposure Response Markers in Peripheral Blood After Switching to a Candidate Modified Risk Tobacco Product: the Tobacco Heating System 2.1 (THS 2.1)
A meta-analysis of human organotypic respiratory cultures exposed to whole cigarette smoke
Comparison of the biological impact of cigarette smoke and a prototypic modified risk tobacco product on human versus rat primary normal bronchial epithelial cells
Effects of Cigarette Smoke Exposure on the Insulin Resistance-Related Metabolic Changes in the High Fat Diet-fed ApoE Knock-Out Mice
High Content Screening analysis of the Biological Impact of Harmful / Potentially Harmful Constituents of Tobacco Smoke
Modeling of flow and evolving aerosol particles dynamics for computing local deposition in air-liquid interface experiments
A prototypic modified risk tobacco product exhibits reduced effects on chemotaxis and transendothelial migration of monocytes compared with a reference cigarette